Edvince AB granted EU Orphan Medicinal Product Designation for EDV2209 in treatment of non-traumatic subarachnoid hemorrhage

On November 8th Edvince AB received a positive decision from the European Commission, granting the EDV2209 drug Orphan Medicinal Product Designation for treatment of non-traumatic subarachnoid hemorrhage.

Edvince AB is a Life Science R&D company that develops a new treatment to minimize brain damage in patients that has suffered a bleeding in the brain – subarachnoid hemorrhage – caused by brain aneurysm.

Edvince AB was granted FDA Orphan-Drug Designation for EDV2209 in treatment of subarachnoid hemorrhage

Edvince AB, a biotech company that is developing a new treatment concept to minimize brain damage subsequent to cerebral ischemia, received a positive response from the US Food and Drug Administration (FDA) on august 3rd, granting the EDV2209 drug orphan-drug designation for treatment of subarachnoid hemorrhage.